Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

CME Medical helps healthcare professionals to gain confidence in end of life and palliative care

CME Medical, is helping healthcare professionals to gain confidence in caring for patients at the end of their lives. Managing end of life care is a challenge for all health staff, as it often involves dealing with complex and emotional communication with patients and relatives and managing patient symptoms. But now highly sophisticated mannequins – which can talk and simulate signs and symptoms of advanced illness – are being used in a pioneering and unique training programme in Birmingham.

30 Oct 2013

Acacia Pharma begins APD403 Phase II study to prevent chemotherapy-induced nausea & vomiting

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of a Phase II study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).

30 Oct 2013

NEI-funded study explores methods to improve diagnosis, treatment of common eye diseases

If you've ever been sleep-deprived, you've probably had a firsthand glimpse of the blood vessels in your eyes. But what you haven't seen—and what many eye care professionals cannot see as well as they would like—are the vessels closest to the retina, the light-sensitive tissue at the back of the eye.

29 Oct 2013

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

New findings from two integrated Phase 3 Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with STELARA- (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo.

29 Oct 2013

Endoscopic ultrasound-guided drainage improves outcomes in patients with pseudocysts

Researchers report that in patients with pseudocysts with viscous debris-laden fluid, endoscopic ultrasound-guided drainage by using a combination of a nasocystic drain and transmural stents improves clinical outcomes and lowers the stent occlusion rate compared with those who underwent drainage via stents alone.

22 Oct 2013

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.

19 Oct 2013

Recombinant hormone could REPLACE calcium supplements

Results from the phase III REPLACE trial of recombinant human parathyroid hormone (rhPTH) indicate the treatment can successfully combat the underlying deficit in hypoparathyroidism.

18 Oct 2013

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

ARIAD Pharmaceuticals, Inc. today announced that it is discontinuing the Phase 3 EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) trial of Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid leukemia.

18 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

Merck to present pharmacokinetic data on once-daily ISENTRESS at EACS

Merck, known as MSD outside the United States and Canada, is presenting pharmacokinetic data this week on investigational formulations of a once daily dose of ISENTRESS at the 14th European AIDS Conference, sponsored by the European AIDS Clinical Society.

17 Oct 2013

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

Boehringer Ingelheim announced the submission of a Marketing Authorisation Application to the European Medicines Agency for the approval of its oral triple angiokinase inhibitor nintedanib, in combination with docetaxel, for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.

17 Oct 2013

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation , today announced the results of the MPACT phase III clinical trial of ABRAXANE® in combination with gemcitabine were published online in the October 16th edition of the New England Journal of Medicine.

17 Oct 2013

Less-healthy patients more prone to recovery room complications

Complications in the recovery room decreased by 58 percent between 1990 and 2010, according to a study presented at the ANESTHESIOLOGY 2013 annual meeting. In a previous study completed in the late 1980s, recovery room complications occurred in 23.7 percent of the patients.

16 Oct 2013

Pregnant women exposed to metoclopramide experience no increased risk of congenital malformations

In an analysis that included more than 40,000 women exposed to the nausea medication metoclopramide in pregnancy, use of this drug was not associated with significantly increased risk of major congenital malformations overall, spontaneous abortion, and stillbirth, according to a study in the October 16 issue of JAMA.

16 Oct 2013

Janssen seeks European marketing approval for combination of once-daily darunavir with cobicistat

Janssen-Cilag International NV, today announced it has submitted a Marketing Authorisation Application to the European Medicines Agency seeking approval for a once-daily single tablet fixed-dose antiretroviral combination product containing darunavir, a protease inhibitor developed by Janssen, with cobicistat, a pharmacokinetic enhancer or boosting agent, developed by Gilead Sciences, Inc. for use in combination with other human immunodeficiency virus medicines.

15 Oct 2013

Acacia Pharma reports positive results from APD515 Phase II study for treatment of xerostomia

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces positive results from its Phase II study of APD515 for the treatment of xerostomia (dry mouth) in advanced cancer patients.

15 Oct 2013

Research shows age does not affect symptom recovery after sports-related concussion

Recent scientific findings have raised the fear that young athletes may fare worse after sustaining a sports-related concussion than older athletes.

15 Oct 2013

AstraZeneca announces Phase III study results of naloxegol in patients with non-cancer pain

AstraZeneca (NYSE: AZN) today announced the results of a Phase III long-term safety and tolerability study of the once-daily 25mg dose of naloxegol, in patients with non-cancer pain and opioid-induced constipation (OIC).

15 Oct 2013

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

14 Oct 2013

Multi-drug therapy can benefit patients at higher risk for post-operative nausea and vomiting

Ninety-seven percent of bariatric surgery patients avoided post-operative nausea and vomiting with the addition of a second drug to the standard treatment given during surgery, according to a study presented at the ANESTHESIOLOGY 2013 annual meeting.

14 Oct 2013

Nausea News and Research

Further Reading

CME Medical helps healthcare professionals to gain confidence in end of life and palliative care

Acacia Pharma begins APD403 Phase II study to prevent chemotherapy-induced nausea & vomiting

NEI-funded study explores methods to improve diagnosis, treatment of common eye diseases

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

Endoscopic ultrasound-guided drainage improves outcomes in patients with pseudocysts

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

Recombinant hormone could REPLACE calcium supplements

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

Merck to present pharmacokinetic data on once-daily ISENTRESS at EACS

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Less-healthy patients more prone to recovery room complications

Pregnant women exposed to metoclopramide experience no increased risk of congenital malformations

Janssen seeks European marketing approval for combination of once-daily darunavir with cobicistat

Acacia Pharma reports positive results from APD515 Phase II study for treatment of xerostomia

Research shows age does not affect symptom recovery after sports-related concussion

AstraZeneca announces Phase III study results of naloxegol in patients with non-cancer pain

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Multi-drug therapy can benefit patients at higher risk for post-operative nausea and vomiting

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News